Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 97 |
| Active Pipeline (Recruiting Now) | 35 (26) |
| Completed vs Stopped Early | 24 / 38 (39.2%) |
| Median Closed Actual Enrollment | 25 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Levine Cancer Institute | Charlotte, NC | 11 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 10 |
| Wake Forest Baptist Health | Winston-Salem, NC | 8 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05766670 | Intramedullary Calcium Sulfate Antibiotic Depot | Phase III | RECRUITING |
| NCT07560826 | The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Wake Forest University Health Sciences Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.